NASDAQ:SNY Sanofi (SNY) Stock Price, News & Analysis $40.20 +0.64 (+1.62%) Closing price 10/7/2026 04:00 PM EasternExtended Trading$40.07 -0.13 (-0.33%) As of 10/7/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Sanofi Stock (NASDAQ:SNY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sanofi alerts:Sign Up Key Stats Today's Range$39.72▼$40.2550-Day Range$39.51▼$46.0252-Week Range$39.18▼$52.68Volume2.08 million shsAverage Volume3.05 million shsMarket Capitalization$97.46 billionP/E Ratio21.05Dividend Yield4.38%Price Target$49.50Consensus RatingHold Company Overview Sanofi is a France-based global healthcare company that develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. Its portfolio focuses on areas including immunology, rare diseases, vaccines, diabetes and other chronic conditions, as well as specialized treatments for selected neurological and inflammatory disorders. The company is known for products such as Dupixent, a biologic used to treat several inflammatory conditions, and a broad range of vaccines marketed through its Sanofi Pasteur business. Sanofi serves patients, healthcare providers and public health organizations in markets across North America, Europe, Asia and other regions worldwide. Sanofi traces its modern corporate history to the formation and combination of several French pharmaceutical businesses, including Sanofi-Synthélabo and Aventis. The company adopted the Sanofi name in 2011 and is headquartered in Paris. Paul Hudson has served as Sanofi’s chief executive officer since 2019.AI Generated. May Contain Errors. Read More Sanofi Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks78th Percentile Overall ScoreSNY MarketRank™: Sanofi scored higher than 78% of companies evaluated by MarketBeat, and ranked 101st out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingSanofi has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 2 strong buy ratings, 3 buy ratings, 10 hold ratings, and 1 sell rating.Upside PotentialSanofi has a consensus price target of $49.50, representing about 23.1% upside from its current price of $40.20.Amount of Analyst CoverageSanofi has only been the subject of 3 research reports in the past 90 days.Read more about Sanofi's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth4.34% Earnings GrowthEarnings for Sanofi are expected to grow by 4.34% in the coming year, from $5.07 to $5.29 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sanofi is 21.05, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.86.Price to Earnings Ratio vs. SectorThe P/E ratio of Sanofi is 21.05, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.56.Price to Earnings Growth RatioSanofi has a PEG Ratio of 1.19. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioSanofi has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Sanofi's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.39% of the float of Sanofi has been sold short.Short Interest Ratio / Days to CoverSanofi has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Sanofi has recently increased by 12.89%, indicating that investor sentiment is decreasing significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend LeadershipSanofi is a leading dividend payer. It pays a dividend yield of 4.46%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthSanofi does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Sanofi is 92.15%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Sanofi will have a dividend payout ratio of 33.27% next year. This indicates that Sanofi will be able to sustain or increase its dividend.Read more about Sanofi's dividend. News and Social Media3.4 / 5News Sentiment0.46 News SentimentSanofi has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Sanofi this week, compared to 6 articles on an average week.Search Interest13 people have searched for SNY on MarketBeat in the last 30 days. This is an increase of 30% compared to the previous 30 days.MarketBeat Follows6 people have added Sanofi to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sanofi insiders have not sold or bought any company stock.Percentage Held by Insiders1.00% of the stock of Sanofi is held by insiders.Percentage Held by Institutions14.03% of the stock of Sanofi is held by institutions.Read more about Sanofi's insider trading history. Receive SNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sanofi and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SNY Stock News HeadlinesPress Release : Availability of the aide-mémoire for Q3 2026 resultsOctober 6 at 1:30 AM | globenewswire.comNovavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks UpOctober 5 at 3:02 PM | 247wallst.comInside the Options Play With a High Historical Win RateIan Cooper's newest strategy targets triple-digit returns in just 9 days. It doesn't work every time, but a 73% win rate and 2,671% return on capital stand on their own. Ian is breaking down the full strategy and offering his newest report at no charge. | TradeWins (Ad)Sanofi (NASDAQ:SNY) Stock Rating Cut to Hold at Wall Street ZenOctober 3, 2026 | americanbankingnews.comRegeneron, Sanofi expand immunology alliance with $1B upfront payment: Here are the key highlightsOctober 1, 2026 | msn.comSanofi, Regeneron Expand Immunology Partnership in $1 Billion DealOctober 1, 2026 | finance.yahoo.comSanofi & Regeneron Expand Alliance With Four Next-Gen AntibodiesOctober 1, 2026 | rttnews.comSanofi, Regeneron Expand Immunology Alliance In Deal Worth Up To $8 BlnOctober 1, 2026 | rttnews.comSee More Headlines SNY Stock Analysis - Frequently Asked Questions How have SNY shares performed this year? Sanofi's stock was trading at $48.46 at the beginning of the year. Since then, SNY stock has decreased by 17.0% and is now trading at $40.20. How were Sanofi's earnings last quarter? Sanofi (NASDAQ:SNY) posted its quarterly earnings data on Thursday, July, 30th. The company reported $2.41 earnings per share for the quarter. The business's revenue was up 16.0% compared to the same quarter last year. Read the conference call transcript. Does Sanofi have any subsidiaries? The following companies are subsidiaries of Sanofi: Kiadis Pharma, Principia BioPharma, Synthorx, Ablynx, Bioverativ, Aventis S.A., Ablynx N.V., and others. Who are Sanofi's major shareholders? Top institutional shareholders of Sanofi include Investors Research Corp, Versant Capital Management Inc, Cooper Financial Group and Central Pacific Bank Trust Division. View institutional ownership trends. How do I buy shares of Sanofi? Shares of SNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sanofi own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sanofi investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings7/30/2026Today10/07/2026Next Earnings (Estimated)10/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (14m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 SNY's financial health is in the Red zone, according to TradeSmith. SNY has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SNY CIK1121404 Webwww.sanofi.com Phone(315) 377-4000Fax33-1-53-77-43-03Employees74,846Year Founded1994Price Target and Rating Average Price Target for Sanofi$49.50 High Price Target$50.00 Low Price Target$49.00 Potential Upside/Downside+23.1%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)$1.91 Trailing P/E Ratio21.05 Forward P/E Ratio7.93 P/E Growth1.19Net Income$8.84 billion Net Margins8.66% Pretax Margin12.00% Return on Equity14.19% Return on Assets7.95% Debt Debt-to-Equity Ratio0.21 Current Ratio0.99 Quick Ratio0.64 Sales & Book Value Annual Sales$49.35 billion Price / Sales1.98 Cash Flow$7.18 per share Price / Cash Flow5.60 Book Value$33.27 per share Price / Book1.21Miscellaneous Outstanding Shares2,424,430,000Free Float2,400,181,000Market Cap$97.46 billion OptionableOptionable Beta0.33 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:SNY) was last updated on 10/8/2026 by MarketBeat.com Staff. From Our PartnersChina ATTACK on American Dollar set for 11/12/2026A former Wall Street Journal personal finance expert warns China may be setting the stage for a major move aga...International Living | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredA dividend every week of the yearMost dividend stocks pay quarterly, leaving long stretches of silence between paydays. For investors covering ...Market Savvy | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as Novemeber. It...Weiss Ratings | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanofi Please log in to your account or sign up in order to add this asset to your watchlist. Share Sanofi With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.